Web site created using create-react-app
Location: China
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Mentions in press and media 16
| Date | Title | Description |
| 22.05.2026 | Nuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in China | NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients SHANGHAI, May 22, 2026 /PRNewswire/ -- Nuance Pharma today announced that the National Medical Products Administration (NMPA) has clear... |
| 20.04.2026 | Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal | Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces ... |
| 12.03.2026 | Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China | Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/... |
| 27.01.2026 | Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chroni... | SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (e... |
| 16.05.2025 | Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD | Statistically significant improvements in lung function Consistent trends of quality of life and exacerbation rate reduction as ENHANCE-1/2 Well tolerated safety profile NDA submission planned for 2H 2025 SHANGHAI, May 16, 2025 /PRNewswire/... |
| 07.02.2025 | Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China | Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects SHANGHAI, Feb. 7, 2025... |
| 24.09.2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| 23.09.2024 | Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia | Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China Extension of Exclusive License and Distribution Agreement to in... |
| 11.09.2024 | Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD | SHANGHAI, Sept. 11, 2024 /PRNewswire/ -- Nuance Pharma today announced it has completed the recruitment of patients for the ENHANCE-CHINA (NCT05743075) study, after planned number of patients have been successfully enrolled. The ENHANCE-CHI... |
| 27.06.2024 | US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD | SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chro... |
Show more